1 Division of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
Am J Respir Cell Mol Biol. 2014 Feb;50(2):347-57. doi: 10.1165/rcmb.2013-0121OC.
Vitamin C (VC) is a potent antioxidant and is essential for collagen synthesis. We investigated whether VC treatment prevents and cures smoke-induced emphysema in senescence marker protein-30 knockout (SMP30-KO) mice, which cannot synthesize VC. Two smoke-exposure experiments using SMP30-KO mice were conducted. In the first one (a preventive study), 4-month-old mice received minimal VC (0.0375 g/l) [VC(L)] or physiologically sufficient VC (1.5 g/l) [VC(S)] and exposed to cigarette smoke or smoke-free air for 2 months. Pulmonary evaluations followed when the mice were 6 months of age. The second study began after the establishment of smoke-induced emphysema (a treatment study). These mice no longer underwent smoke exposure but received VC(S) or VC(L) treatment for 2 months. Morphometric analysis was performed, and measurements of oxidative stress, collagen synthesis, and vascular endothelial growth factor in the lungs were evaluated. Chronic smoke exposure caused emphysema (29.6% increases of mean linear intercepts [MLI] and 106.5% increases of destructive index compared with the air-only group) in 6-month-old SMP30-KO mice, and this emphysema closely resembled human chronic obstructive pulmonary disease. Smoke-induced emphysema persisted in the VC(L) group after smoking cessation, whereas VC treatment provided pulmonary restoration (18.5% decrease of MLI and 41.3% decrease of destructive index compared with VC(L) group). VC treatment diminished oxidative stress, increased collagen synthesis, and improved vascular endothelial growth factor levels in the lungs. Our results suggest that VC not only prevents smoke-induced emphysema in SMP30-KO mice but also restores emphysematous lungs. Therefore, VC may provide a new therapeutic strategy for treating chronic obstructive pulmonary disease in humans.
维生素 C(VC)是一种有效的抗氧化剂,对于胶原蛋白合成至关重要。我们研究了 VC 治疗是否可以预防和治疗衰老相关蛋白 30 敲除(SMP30-KO)小鼠的吸烟诱导的肺气肿,因为 SMP30-KO 小鼠不能合成 VC。我们进行了两项 SMP30-KO 小鼠的吸烟暴露实验。在第一项实验(预防性研究)中,4 月龄的小鼠接受低剂量 VC(0.0375 g/L)[VC(L)]或生理足够剂量 VC(1.5 g/L)[VC(S)],并接受吸烟或无烟空气暴露 2 个月。当小鼠 6 月龄时进行肺功能评估。第二项研究开始于建立吸烟诱导的肺气肿后(治疗性研究)。这些小鼠不再接受吸烟暴露,但接受 VC(S)或 VC(L)治疗 2 个月。进行形态计量学分析,并评估肺部的氧化应激、胶原蛋白合成和血管内皮生长因子。慢性吸烟暴露导致 6 月龄 SMP30-KO 小鼠发生肺气肿(与仅空气组相比,平均线性截距增加 29.6%,破坏性指数增加 106.5%),这种肺气肿与人类慢性阻塞性肺疾病非常相似。吸烟停止后,VC(L)组仍存在吸烟诱导的肺气肿,而 VC 治疗提供了肺功能恢复(与 VC(L)组相比,平均线性截距降低 18.5%,破坏性指数降低 41.3%)。VC 治疗降低了氧化应激,增加了胶原蛋白合成,并改善了肺部的血管内皮生长因子水平。我们的结果表明,VC 不仅可以预防 SMP30-KO 小鼠的吸烟诱导的肺气肿,还可以恢复肺气肿的肺。因此,VC 可能为治疗人类慢性阻塞性肺疾病提供一种新的治疗策略。